Medmira Inc (TSE:MIR)
:MIR
Want to see TSE:MIR full AI Analyst Report?
Top Page
Medmira
(MIR)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.07
▼(-4.29% Downside)
Action:Reiterated
Date:04/09/26
The score is driven primarily by very weak financial performance (shrinking revenue, large losses, negative equity, rising debt, and ongoing cash burn). Technicals add modest downside pressure with the stock below major moving averages and negative MACD. Valuation does not offset these risks because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Proprietary technology platform
MedMira's proprietary Rapid Vertical Flow Technology provides a durable product differentiation and R&D foundation. Owning the core platform supports multiple assay development, potential licensing or partner deals, and creates a barrier to entry versus generic lateral-flow competitors.
Negative Factors
Shrinking, tiny revenue base
Revenue has eroded to a trivial base and continues declining, leaving insufficient scale to cover fixed costs or fund commercialization. Sustained negative gross profit and large net losses mean the core business is not self-sustaining, forcing reliance on external financing unless material revenue growth is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary technology platform
MedMira's proprietary Rapid Vertical Flow Technology provides a durable product differentiation and R&D foundation. Owning the core platform supports multiple assay development, potential licensing or partner deals, and creates a barrier to entry versus generic lateral-flow competitors.
Read all positive factors
Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$45.61M
Dividend YieldN/A
Average Volume (3M)94.91K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-31.89%
EPS Growth21.88%
CountryCA
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding701,730,600
10 Day Avg. Volume79,718
30 Day Avg. Volume94,909
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)-2.47
Price to Sales (P/S)232.06
P/FCF Ratio-17.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medmira Business Overview & Revenue Model
Company Description
MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific r...
How the Company Makes Money
MedMira makes money primarily by selling in vitro diagnostic (IVD) test products and related consumables to healthcare providers, laboratories, clinics, government/public-health programs, and distributors. Its core revenue stream is product revenu...
Medmira Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 188.50K | 240.51K | 412.57K | 432.53K | 952.13K | 2.14M |
| Gross Profit | -1.55M | -990.25K | 226.49K | -434.91K | 304.03K | 1.72M |
| EBITDA | -2.22M | -3.13M | -2.13M | -1.58M | -1.07M | 185.30K |
| Net Income | -3.49M | -4.52M | -3.33M | -2.68M | -1.83M | -675.80K |
Balance Sheet | ||||||
| Total Assets | 3.58M | 3.68M | 6.07M | 3.65M | 3.83M | 3.89M |
| Cash, Cash Equivalents and Short-Term Investments | 96.20K | 14.91K | 2.10M | 13.18K | 33.46K | -2.30M |
| Total Debt | 9.79M | 10.71M | 9.56M | 9.27M | 8.30M | 11.54M |
| Total Liabilities | 27.61M | 26.24M | 24.11M | 18.68M | 16.19M | 19.61M |
| Stockholders Equity | -24.03M | -22.56M | -18.04M | -15.03M | -12.36M | -15.72M |
Cash Flow | ||||||
| Free Cash Flow | -1.96M | -3.15M | -3.68M | -1.27M | -1.95M | -541.19K |
| Operating Cash Flow | -1.96M | -3.15M | -2.94M | -1.27M | -1.88M | -504.64K |
| Investing Cash Flow | 0.00 | -7.47K | -742.53K | -1.27K | -69.72K | -36.55K |
| Financing Cash Flow | 1.76M | 1.07M | 5.77M | 1.25M | 1.99M | 139.32K |
Medmira Technical Analysis
Negative
0.07
Price Trends
0.06
Negative
0.06
Negative
0.07
Negative
Market Momentum
<0.01
Positive
48.08
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.07, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.
Medmira Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$59.66M | 38.36 | 3.31% | ― | -3.44% | -57.64% | |
53 Neutral | C$41.94M | -7.27 | -8.01% | ― | -34.81% | -453.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$56.65M | -4.75 | ― | ― | ― | 49.13% | |
42 Neutral | C$45.61M | -12.98 | ― | ― | -31.89% | 21.88% | |
41 Neutral | C$40.93M | -4.37 | ― | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:MIR
Medmira
0.07
-0.02
-18.75%
TSE:COV
Covalon Technologies
2.16
-0.06
-2.70%
TSE:MBX
Microbix Biosystms
0.31
<0.01
1.67%
TSE:SVA
Sernova
0.15
-0.02
-9.09%
TSE:NRX
NurExone Biologic
0.56
-0.13
-18.84%
TSE:DTC
Defence Therapeutics
0.54
-0.19
-26.03%
Medmira Corporate Events
Business Operations and StrategyFinancial Disclosures
MedMira Expands McKesson Partnership as Quarterly Revenue Falls and Loss Widens
Negative
Apr 2, 2026
MedMira reported second-quarter fiscal 2026 results marked by weaker revenue and a wider net loss, alongside a strategic expansion of its distribution network. The company signed a major agreement with McKesson in the U.S. and Canada, broadening a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.